Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22861662 | 0.98 | EPHX1 (0.36) | EPHX1HRH4HRH3ADRB2KDM4E | |
| SCHEMBL22861675 | 0.98 | EPHX1 (0.36) | EPHX1HRH4HRH3ADRB2KDM4E | |
| SCHEMBL23945626 | 0.98 | EPHX1 (0.36) | EPHX1HRH4HRH3ADRB2KDM4E | |
| SCHEMBL23945439 | 0.98 | EPHX1 (0.36) | EPHX1HRH4HRH3ADRB2KDM4E | |
| SCHEMBL18674314 | 0.86 | — | — | |
| SCHEMBL20322090 | 0.80 | EPHX1 (0.47) | EPHX1 | |
| SCHEMBL23806852 | 0.80 | — | — | |
| SCHEMBL21106977 | 0.79 | — | — | |
| SCHEMBL25466802 | 0.78 | EPHX1 (0.41) | EPHX1HRH4HRH3ADRB2KDM4E | |
| SCHEMBL22861925 | 0.78 | EPHX1 (0.50) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117168-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | COLE RODERIC O (US) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117168-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | JAK2, JAK3, JAK1 | EPHX1 3903/4885HRH4 4149/4885HRH3 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.